{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:16:28Z","timestamp":1780514188034,"version":"3.54.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,9]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay. Blinatumomab given prior to transplant reduces MRD and results in favorable leukemia-free survival, toxicity, and overall survival.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018025726","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T16:59:00Z","timestamp":1561568340000},"page":"1926-1929","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-8456","authenticated-orcid":false,"given":"Amy K.","family":"Keating","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine and The Children\u2019s Hospital of Colorado, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Gossai","sequence":"additional","affiliation":[{"name":"Children\u2019s Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine and The Children\u2019s Hospital of Colorado, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine and The Children\u2019s Hospital of Colorado, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Doan","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Burke","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine and The Children\u2019s Hospital of Colorado, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"issue":"14","key":"2020021108162060900_B1","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020021108162060900_B2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"issue":"22","key":"2020021108162060900_B3","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"1 Suppl","key":"2020021108162060900_B4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbmt.2008.11.009","article-title":"Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease\/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse","volume":"15","author":"Pulsipher","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021108162060900_B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2020021108162060900_B6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020021108162060900_B7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020021108162060900_B8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1517\/14712598.2015.1041373","article-title":"Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer","volume":"15","author":"Stieglmaier","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"36","key":"2020021108162060900_B9","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020021108162060900_B10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fonc.2014.00063","article-title":"Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE(\u00ae) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","volume":"4","author":"Hoffman","year":"2014","journal-title":"Front Oncol"},{"issue":"7","key":"2020021108162060900_B11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","article-title":"Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab","volume":"99","author":"Schlegel","year":"2014","journal-title":"Haematologica"},{"issue":"36","key":"2020021108162060900_B12","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020021108162060900_B13","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1056\/NEJMc1704012","article-title":"Blinatumomab for acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2020021108162060900_B14","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2020021108162060900_B15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020021108162060900_B16","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/bmt.2017.186","article-title":"Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation","volume":"52","author":"Zeng","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2020021108162060900_B17","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.3390\/jcm6070066","article-title":"When less is good, is none better? The prognostic and therapeutic significance of peri-transplant minimal residual disease assessment in pediatric acute lymphoblastic leukemia","volume":"6","author":"Lamble","year":"2017","journal-title":"J Clin Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/13\/1926\/1631986\/advances025726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/13\/1926\/1631986\/advances025726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:20:40Z","timestamp":1581409240000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/13\/1926\/246603\/Reducing-minimal-residual-disease-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":17,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018025726","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]}}}